Notice of Preliminary Results

Oxford, UK - 30 March 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, will be announcing its preliminary results for the twelve months ended 31 December 2022 on Thursday, 20 April 2023.

Frank Mathias, Chief Executive Officer, Stuart Paynter, Chief Financial Officer, and Kyriacos Mitrophanous, Chief Scientific Officer will host a briefing and Q&A session for analysts at 13:00 BST / 8:00 ET on the day of results at the London Stock Exchange, 10 Paternoster Square, London, EC4M 7LS.  Simultaneous to the meeting, a webcast and conference call will take place and details will be made available on the Company's website at www.oxb.com. A replay of the webcast will be made available shortly afterwards.

Please contact Consilium Strategic Communications for further details.

-Ends-

Enquiries:       

Oxford Biomedica plc:

Frank Mathias, Chief Executive Officer - T: +44 (0)1865 783 000

Stuart Paynter, Chief Financial Officer - T: +44 (0)1865 783 000

Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488 / E: ir@oxb.com

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E: ir@oxb.com

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

Mary-Jane Elliott / Matthew Cole            / Matthew Neal

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Further information is available at www.oxb.com.